
24/7 Wall St. has put together a few stocks that are on the move in the market and provided some color and background information on each, including the consensus price target and range.
KaloBios Pharmaceuticals Inc. (NASDAQ: KBIO) saw its shares soar in Friday’s session, extending its breakout from Thursday. The company is initiating an open-label Phase 1 study designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated chronic myelomonocytic leukaemia patients. Also its KB004 is currently in clinical development in the Phase 2 expansion portion of an open-label Phase 1/2 study in hematologic malignancies. Shares of KaloBios were up 51% to $4.58 on Friday. The stock has a consensus analyst price target of $5.00 and a 52-week trading range of $1.71 to $17.20.
Netflix Inc. (NASDAQ: NFLX) is continuing to crumble from its all-time high set earlier this summer. Some traders believe that Netflix is currently in a bear market. And with a high price-to-earnings (P/E) ratio at 451 against 2015 expected earnings, the stock will not fare well if it is in fact in a bear market. Netflix shares were down 1.8% to $99.20. The stock has a consensus price target of $118.70 and a 52-week range of $45.08 to $129.29.
ALSO READ: 5 Analyst Stocks With Massive Upside Calls This Week
Joy Global Inc. (NYSE: JOY) was absolutely decimated in Thursday’s session. Shares closed down 14.6% after catastrophic earnings. In Friday’s session, traders corrected the downturn and shares bounced. Shares of Joy were up 3.3% to $19.53. The consensus analyst price target is $34.56, and the 52-week range is $17.70 to $60.53.
BP PLC (NYSE: BP) has been the victim of the oil trade this week. Crude oil prices skyrocketed around 8% on Monday and nearly broke the $50 mark. However, since then prices have crumbled and then recovered back to the $46 level. This volatility has called into question the viability of major oil companies, and BP appears to be the hardest hit in Friday’s session. Shares of BP were down 4.7% at $30.89. The consensus price target is $41.21, and the 52-week range is $30.53 to $48.11.